ORSERDUTM (ELACESTRANT)
Publications
Elacestrant in ER+, HER2– MBC with ESR1-mutated tumors:
Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and in Clinical Subgroups
Journal of Clinical Oncology (2022): Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial
Journal of Clinical Oncology (2021): Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
Presentations
EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting. SABCS 2022.
ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating elacestrant in Various Combinations in Women and Men with Metastatic Breast Cancer (mBC). SABCS 2022.
Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard of Care Endocrine Monotherapy for ER+/HER2- Advanced/Metastatic Breast Cancer: Subgroup Analysis from EMERALD. ESMO 2022.
EMERALD: Subgroup analysis of patients with no prior chemotherapy in a phase 3 trial evaluating elacestrant versus investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC). ASCO 2022.
Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on priorendocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial. SABCS 2021.
Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. SABCS 2019.
ELZONRIS® (TAGRAXOFUSP)
Publications
Journal of Clinical Oncology (2022): Long-Term Benefits of Tagraxofusp for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm
New England Journal of Medicine (2019): Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Presentations
Phase I Study of Tagraxofusp +/- Chemotherapy in Pediatric Patients with R/R CD123-Expressing Hematologic Malignancies: A TACL Consortium Trial. ASH 2022.
Patients with BPDCN and Prior/Concomitant Hem Malignancies: Subgroup Analysis of Pivotal Trial. ASH 2022.
Preliminary Results from an Observational Study of Patients with BPDCN Treated in the European EAP. ASH 2022.
Tagraxofusp: Phase 1/2 Study of Tagraxofusp in Patients with Relapsed/Refractory MF. ASH 2021.
Tagraxofusp Subanalysis of Pivotal Trial in BPDCN by Age and Baseline Disease. ASH 2021.
SL-801
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors. ESMO 2019.
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors. ESMO 2018.
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors. ASCO 2018.
Ongoing Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors; Interim Results. ESMO 2017.
SL-801, a novel, reversible inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with broad and potent anti-cancer activity. ASH 2015.
SL-701
Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM). SNO 2018
Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM). ESMO 2018
Phase 2 trial of SL-701 in Relapsed/Refractory (r/r) Glioblastoma (GBM) Indicates Preliminary Correlation of Immune Response with Longer-term Survival. ASCO 2018.
Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and Survivin, in adults with second-line recurrent GBM. SNO 2017.
Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and Survivin, in adults with second-line recurrent GBM: Interim results. SNO 2016.
Initiation of clinical studies with SL-701, a synthetic multi-peptide vaccine with enhanced immunostimulatory properties targeting multiple glioma-associated antigens, in adults with first recurrence of glioblastoma. SNO 2014.